Skip to main content
. 2024 Oct 21;12(11):897–906. doi: 10.14218/JCTH.2024.00270

Fig. 5. Validation of the hsa_circ_0001726/miR-140-3p/KRAS axis in HCC.

Fig. 5

(A) Predicted binding sites between hsa_circ_0001726 and miR-140-3p. (B) The correlation between the expression levels of hsa_circ_0001726 and miR-140-3p. (C) RNA pull-down assay for hsa_circ_0001726. (D) Dual-luciferase reporter assay for hsa_circ_0001726. (E) Predicted binding sites between miR-140-3p and KRAS. (F) The correlation between the expression levels of miR-140-3p and KRAS. (G) RNA pull-down assay for KRAS mRNA. (H) Dual-luciferase reporter assay for KRAS mRNA. ***p < 0.001. ns, not significant. HCC, hepatocellular carcinoma.